ESRA, NCT05339087: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH |
|
|
| Recruiting | 2 | 70 | Europe | Riociguat Oral Tablet, MK-4836, ATC Code: C02KX05, Placebo | Heidelberg University, Merck Sharp & Dohme LLC | Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue | 10/25 | 06/26 | | |